Evidence map›Paper›PMID 40705265›Full record

ArticleAnnals of surgical oncology2025

Investigating the Prognostic Impact of Postpartum Diagnosis in Women with De Novo Stage IV Inflammatory Breast Cancer.

Srivarshini C Mohan, Jennifer H Chen, Rebecca S Slack Tidwell, Megumi Kai, Anthony Lucci, Wendy A Woodward, Helen M Johnson

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Srivarshini C MohanDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer H ChenDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca S Slack TidwellDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Megumi KaiMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony LucciDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wendy A WoodwardMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Helen M JohnsonDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hmjohnson1@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPostpartum breast cancer (PPBC) and inflammatory breast cancer (IBC) are associated with poor prognosis. Despite similarities in mechanisms, data on the intersection of PPBC and IBC are limited, particularly for stage IV disease. We aimed to evaluate the impact of postpartum diagnosis on survival of patients with metastatic IBC. PATIENTS AND

methodsWe retrospectively analyzed data from a prospectively maintained, single-center IBC registry for patients diagnosed with de novo metastatic IBC from 2007 to 2023. Clinical stage was subclassified into IVA, IVB, IVC, and IVD per the staging system by Plichta and colleagues. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier. Multivariate Cox regression analyses were performed.

resultsAmong 167 patients, 15 (8.9%) were nulliparous at diagnosis, 23 (13.8%) were 0-5 years postpartum, 11 (6.6%) were 6-10 years postpartum, 31 (18.6%) were 11-20 years postpartum, and 87 (52.1%) were > 20 years postpartum; 40 (24.0%) patients had stage IVB disease whereas 47 (28.1%) had stage IVC and 80 (47.9%) had stage IVD disease. Median follow-up was 84.1 months. Median OS and 95% confidence interval were 37.9 months (32.9-49.8); median PFS was 14.1 months (12.7-18.1 months). OS and PFS did not differ significantly by postpartum group (log rank p > 0.05). On multivariate analyses controlling for Plichta stage (p = 0.001), age, and treatment, postpartum group was not significantly associated with either survival outcome (p > 0.05).

conclusionsIn this cohort of patients with metastatic IBC, postpartum diagnosis did not significantly impact survival. Our findings suggest that the aggressive characteristics of IBC outweigh the poor prognosis associated with postpartum diagnosis.

Indexed as

Inflammatory Breast NeoplasmsPostpartum PeriodAdultFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingPregnancyPrognosisProspective StudiesRetrospective StudiesSurvival RateBreast cancerInflammatory breast cancerPostpartumPregnancyStage IV

Identifiers

PMID40705265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.